280Bio Provides Update on the KRAS Inhibitor TEB-17231 at th

280Bio, Inc. a clinical stage biotechnology company, focused on the development of precision oncology medicines, today announced a presentation featuring the Company's lead development

Related Keywords

Houston , Texas , United States , China , Florida , Shanghai , Orlando , Yingli Pharma , Xu Zusheng , Michael Hui , Head Of Research , Shanghai Yingli Pharmaceutical Co Ltd , Development Of Yingli Pharma , Md Anderson Cancer Center , Bio Inc , Session Category , Cellular Biology , Session Title , Ras Related Signaling , Monday April , Poster Board , Cancer Center , General Manager , San Francisco Bay Area , 280bio , Acrmeeting , Ealth Press Release ,